


# COVID-19 UPDATE

## Facts & Figures


Issued July 22, 2021




### Last Contagion Figures

- **July 21: 519,305 7-day average new cases**, compared to 469,659 a week ago and 359,136 a month ago. Now confirmed **191,874,794 cases worldwide** vs 188,239,660 cases last week.
- 4,126,076 people have died (2.2% of confirmed cases) and 173,603,030 have recovered (90.5%).
- **Europe:** 51,683,116 cases; 7-day avg growth of 124,876 vs 91,786 a week ago and 31,173 a month ago.
- **USA:** 34,226,806 cases; 7-day avg growth of 39,939 vs 25,255 a week ago and 11,363 a month ago.
- **Vaccines:** around 3.73 billion doses have been administered globally, of which 338 million in the **USA** and 436 million in the **EU**. 109 vaccines are in clinical evaluation and 184 vaccines are in preclinical evaluation.


Global Confirmed Cases




Global Infected Status




Global new cases per day



Global New Cases & Deaths




daily cases & deaths per million, 7-day avg  
top 5 european economies\*



\* Overall daily cases and deaths per million people for France, Italy, Spain, Germany and the UK


People vaccinated ('000)









source: Our World In Data











Percentage of people vaccinated

source: Our World In Data










TOP 10 most hit countries						
Country	Cases			Deaths		
	Total	last 7D avg	last month	Total	last 7D avg	last month
USA	34,226,806	+ 39,939	+ 23,184	609,862	+ 246	+ 248
India	31,256,839	+ 38,577	+ 41,953	419,021	+ 1,000	+ 965
Brazil	19,474,489	+ 37,823	+ 46,561	545,690	+ 1,170	+ 1,373
Russia	6,030,240	+ 24,748	+ 23,633	150,705	+ 775	+ 708
France	5,911,601	+ 11,697	+ 5,331	111,554	+ 20	+ 25
UK	5,563,006	+ 47,114	+ 31,969	128,896	+ 52	+ 31
Turkey	5,554,317	+ 7,738	+ 5,956	50,709	+ 49	+ 48
Argentina	4,798,851	+ 13,742	+ 16,884	102,818	+ 367	+ 423
Colombia	4,679,994	+ 16,375	+ 23,321	117,482	+ 449	+ 555
Italy	4,297,337	+ 3,070	+ 1,497	127,905	+ 11	+ 20


Most hit regions						
Country	Cases			Deaths		
	Total	last 7D avg	last month	Total	last 7D avg	last month
Asia	58,103,358	+ 216,164	+ 185,057	929,554	+ 4,344	+ 3,542
Europe	51,683,116	+ 124,876	+ 79,720	1,044,831	+ 269	+ 339
North America	40,723,628	+ 63,518	+ 42,032	915,196	+ 628	+ 598
South America	34,794,867	+ 75,712	+ 97,481	1,069,373	+ 3,549	+ 3,119
Africa	6,383,871	+ 37,716	+ 37,637	161,040	+ 866	+ 769
Oceania	92,867	+ 1,285	+ 734	1,431	+ 13	+ 6
Others	723	-	-	15	-	-

\* Regional classification according to the United Nations Geoscheme; Russia included in Asia


**Google Mobility Index: Workplaces**  
Percentage change from baseline, 7-day avg



**Apple Mobility Index**  
Percentage change from baseline, 7-day avg



**OpenTable: Seated Diners at Restaurants**  
change from 2019, 7-day avg



COVID-19 candidate vaccines		
Stage	Phase	N°
Clinical Evaluation	4	8
	3	19
	2/3	8
	2	10
	1/2	27
	1	37
Total Clinical Evaluation		109
Preclinical Evaluation		184

\*Data from the World Health Organization landscape documents

Note: Data sources: WHO, CDC, ECDC, JHU, Worldometers.info, state and national government health departments, local media reports, Google Mobility Report, OpenTable, Bloomberg, Oxford University, OurWorldInData, Harvard Chan school of public health, Al Jazeera. The day is reset after midnight GMT+0. For additional information regarding the data collected and presented in this document please contact [mattia.mammarella@generali-invest.com](mailto:mattia.mammarella@generali-invest.com)

## Main news

- A study in the New England Journal of Medicine found that Pfizer was 88% effective at preventing symptomatic disease from the Delta variant with both doses, compared with 93.7% against the Alpha variant.
- US borders with Mexico and Canada will remain closed to non-essential travel for another month.
- Pfizer and BioNTech have struck a deal with South Africa-based company Biovac to produce COVID-19 vaccines for the African Union (AU).
- France has rolled out a new COVID-19 health pass amid a surge in infections. From Wednesday, people wanting to visit cinemas, museums, sports matches, and other cultural venues will now be required to show proof of vaccination against COVID-19, a negative test, or recent recovery from the virus.
- Canada will allow American tourists who are fully vaccinated against COVID-19 to enter the country as of August 9, ending a 16-month ban on most non-essential travel.
- The British government has lifted all pandemic restrictions in England despite scientists' warnings that the move will further drive an already surging pandemic and risk creating new variants.
- The Australian city of Sydney has ordered a shutdown of building sites, banned non-essential retail and threatened fines for employers who make staff come into the office as new COVID-19 cases kept rising three weeks into a citywide lockdown.

# Imprint

<b>Head of Research</b>	Vincent Chaigneau (vincent.chaigneau@generali-invest.com)	
<b>Head of Macro &amp; Market Research:</b>	Dr. Thomas Hempell, CFA (thomas.hempell@generali-invest.com)	
<b>Team:</b>	Elisabeth Assmuth (elisabeth.assmuth@generali-invest.com) Elisa Belgacem (elisa.belgacem@generali-invest.com) Radomír Jáč (radomir.jac@generali.com) Jakub Krátký (jakub.kratky@generali.com) Michele Morganti (michele.morganti@generali-invest.com) Vladimir Oleinikov, CFA (vladimir.oleinikov@generali-invest.com) Dr. Martin Pohl (martin.pohl@generali.com) Dr. Thorsten Runde (thorsten.runde@generali-invest.com) Dr. Christoph Siepmann (christoph.siepmann@generali-invest.com) Dr. Florian Späte, CIIA (florian.spaete@generali-invest.com) Dr. Martin Wolburg, CIIA (martin.wolburg@generali-invest.com) Paolo Zanghieri, PhD (paolo.zanghieri@generali.com)	
<b>Head of Insurance and AM Research:</b>	Michele Morganti (michele.morganti@generali-invest.com)	
<b>Team:</b>	Raffaella Bagata (raffaella.bagata@generali.com) Alberto Cybo-Ottone, PhD (alberto.cybo@generali.com) Mattia Mammarella (mattia.mammarella@generali-invest.com) Roberto Menegato (roberto.menegato@generali.com) Giovanni Millo, PhD (giovanni.millo@generali.com) Antonio Salera, PhD (antonio.salera@generali.com) Cristiana Settimo (cristiana.settimo@generali.com) Federica Tartara, CFA (federica.tartara@generali.com)	
<b>Issued by:</b>	Generali Insurance Asset Management S.p.A., Research Department	
<b>In Italy:</b> Generali Insurance Asset Management S.p.A Società di gestione del risparmio  Piazza Tre Torri 20145 Milano MI, Italy  Via Niccolò Machiavelli, 4 34132 Trieste TS, Italy	<b>In France:</b> Generali Insurance Asset Management S.p.A Società di gestione del risparmio  2, Rue Pillet-Will 75009 Paris Cedex 09, France	<b>In Germany:</b> Generali Insurance Asset Management S.p.A. Società di gestione del risparmio  Tunisstraße 19-23 50667 Cologne, Germany

[www.generali-investments.com](http://www.generali-investments.com)

This document is based on information and opinions which Generali Insurance Asset Management S.p.A. Società di gestione del risparmio considers as reliable. However, no representation or warranty, expressed or implied, is made that such information or opinions are accurate or complete. Generali Insurance Asset Management S.p.A. Società di gestione del risparmio periodically updating the contents of this document, relieves itself from any responsibility concerning mistakes or omissions and shall not be considered responsible in case of possible changes or losses related to the improper use of the information herein provided. Opinions expressed in this document represent only the judgment of Generali Insurance Asset Management S.p.A. Società di gestione del risparmio and may be subject to any change without notification. They do not constitute an evaluation of any strategy or any investment in financial instruments. This document does not constitute an offer, solicitation or recommendation to buy or to sell financial instruments. Generali Insurance Asset Management S.p.A. Società di gestione del risparmio is not liable for any investment decision based on this document. Generali Investments may have taken, and may in the future take, investment decisions for the portfolios it manages which are contrary to the views expressed herein. Any reproduction, total or partial, of this document is prohibited without prior consent of Generali Insurance Asset Management S.p.A. Società di gestione del risparmio. Generali Investments is part of the Generali Group which was established in 1831 in Trieste as Assicurazioni Generali Austro-Italiane. Generali Investments is a commercial brand of Generali Investments Partners S.p.A. Società di gestione del risparmio, Generali Insurance Asset Management S.p.A. Società di gestione del risparmio, Generali Investments Luxembourg S.A. and Generali Investments Holding S.p.A..